Search





Search





Markets
/
Stocks
/
crl
/

Charles River Laboratories International Inc

CRL

Add to Watchlist

234.800USD

-5.630-2.34%

Close 07-29 16:00（ET）Quotes delayed by 15 min

11.31BMarket Cap

LossP/E TTM

Charles River Laboratories International Inc

234.800

-5.630-2.34%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-2.34%

5 Days

+7.36%

1 Month

+4.09%

6 Months

+10.92%

Year to Date

+17.71%

1 Year

+31.58%

Key Figures

238.780Open

242.400High

1.05MVolume

LossP/E TTM

18.79P/E Dynamic

--Dividend TTM

2.19%Turnover Ratio

240.430Prev. Close

234.180Low

144.93MTurnover

1098.34P/E Static

3.85P/B

0.00%Div Yield TTM

-2.39%ROA

228.88052wk High

1.29Volume Ratio

10.30MNet Profit

48.17MShares

-3.7180EPS TTM

1.46Beta

-6.02%ROE

132.58352wk Low

3.42%Amplitude

30.90%Gross Margin

11.31BMarket Cap

2.30Reward/Risk

2.62%Risk Rate

TradingKey Stock Score of Charles River Laboratories International Inc

Currency: USD Updated: 2026-07-29

Key Insights

Charles River Laboratories International Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 231.44.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Charles River Laboratories International Inc's Score

Industry at a Glance

Industry Ranking

20 / 384

Overall Ranking

66 / 4277

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Charles River Laboratories International Inc Highlights

StrengthsRisks

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -63.15, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 56.13M shares, decreasing 12.43% quarter-over-quarter.

Held by John Rogers

Star Investor John Rogers holds 1.51M shares of this stock.

Analyst Rating

Based on 19 analysts

Buy

Current Rating

231.445

Target Price

+3.19%

Upside Space

Charles River Laboratories International Inc News

GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

TradingKey - On April 16, 2026, OpenAI released GPT-Rosalind, a large language model specifically designed for life sciences research. Initial users include pharmaceutical giant Amgen (AMGN), vaccine manufacturer Moderna (MRNA), and the Allen Institute. Following the announcement, the CRO sector saw a broad decline, with IQVIA Holdings (IQV) falling 3.5% and Charles River Laboratories (CRL) dropping 2.6%. Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR) both tumbled over 5% at one point.

TradingKeyFri, Apr 17